Breaking News

Financial Report: Gilead

July 26, 2013

Revenues climb 15% in the quarter

Gilead

2Q Revenues: $2.7 billion (+15%)

2Q Earnings: $767.6 million (+9%)

YTD Revenues: $5.1 billion (+12%)

YTD Earnings: $1.5 billion (+30%)

Comments: Antiviral product sales were up 15% to $2.3 billion in the quarter, driven by Viread, up 16% to $250.2 million, and Complera/Eviplera, up 159% to $188.7 million, along with Atripla sales, up 4% to $938.1 million, Truvada sales, up 3% to $807.8 million. Additionally, the company launched Stribild, which generated $99.4 million in sales. Cardiovascular product sales (Letairis and Ranexa) were $234.9 million in the quarter, up 19%. Royalty, contract and other revenues were $110.1 million, up 31%.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision